Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

tions 18 Safe Harbor Statement 20 Explanation of Non GAAP Measures 21 Trademarks 21

Dial in details for the live conference call  for investors 14:00 BST/9:00 EDT on April 26, 2012:

UK dial in:            0800 077 8492 or 0844 335 0351

US dial in:            1 866 8048688 or 1 718 3541175

International dial in:        +44 844 335 0351

Password/Conf ID:        338270

Live Webcast:            http://www.shire.com/shireplc/en/investors

OVERVIEW OF FIRST QUARTER 2012 FINANCIAL RESULTS

1.    Product sales

For the three months to March 31, 2012 product sales increased by 24% to $1,106.9 million (Q1 2011: $889.3 million) and represented 94% of total revenues (Q1 2011: 91%).

US Exit Market Product Highlights Year on year growth Share[(1)] Product Sales $M Sales CER US Rx[(1)] VYVANSE 260.0 +29% +29% +23% 17% REPLAGAL 134.4 +28% +31% n/a[(3)] n/a[(3)] ELAPRASE 125.6 +21% +24% n/a[(2)] n/a[(2)] ADDERALL XR 111.4 +0% +0% +4% 7% LIALDA/MEZAVANT(R) 90.0 +3% +4% +3% 21% VPRIV 71.7 +22% +23% n/a[(2)] n/a[(2)] INTUNIV 68.5 +63% +63% +54% 4% PENTASA(R) 65.8 +2% +2% -6% 14% DERMAGRAFT 48.8 n/a n/a n/a[(2)] n/a[(2)] FOSRENOL 45.5 +10% +12% -23% 5% FIRAZYR 19.7 +272% +280% n/a[(2)] n/a[(2)] OTHER 65.5 -4% -2% n/a n/a Total product sales 1,106.9 +24% +26%

[(1)]    Data provided by IMS Health National Prescription Audit ("IMS NPA"). Exit market share represents the average monthly US market share in the month ended March 31, 2012.

[(2)]    IMS NPA Data not available.

[(3)]    Not sold in the US in Q1 2012.

VYVANSE - ADHD

VYVANSE product sales grew strongly in Q1
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 North America Gynecological Devices ... GlobalData,s new report, "North America Gynecological ... data on the North America Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... significant growth during the last decade due ... environment, natural calamities and technological advancements. This ... strategies within various segments of the ambulance ... as transportation equipment, blood and hemorrhage control ...
(Date:9/17/2014)... 17, 2014  Decision Resources Group finds ... eligible for biologic therapy, only a proportion ... gastroenterologists cite patients, discomfort with biological therapy ... rates, followed by cost-related issues and payer ... biologics, Janssen Biotech,s Remicade and AbbVie,s Humira ...
Breaking Medicine Technology:North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... 2012  Sensitech Inc., the global leader in cold ... Transport Association (IATA) has deemed Sensitech,s full range ... in compliance with the 53rd edition of the ... published by the United Nations.   The size and ...
... FRANCISCO, April 26, 2012 Onyx Pharmaceuticals, Inc. (Nasdaq: ... Food and Drug Administration,s (FDA) Oncologic Drugs Advisory Committee ... for carfilzomib for the treatment of patients with relapsed ... two prior therapies. ODAC will review carfilzomib at its ...
Cached Medicine Technology:Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 3
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... 18, 2014 The global ablation technologies ... 9.6% from 2014 to 2019. Although mature markets (such ... larger shares in the ablation technologies market in 2014, ... highest CAGR of 12.8% in the next five years.Factors ... infrastructure, growing number of hospitals and surgical centers, and ...
(Date:9/17/2014)... 18, 2014 iFitDress.com, a renowned wedding dress ... petite evening dresses . All these outfits are now ... discounted shipping costs. , “iFitDress.com is a professional company ... We are now busy selling our new collection of petite ... an order above $800 can get free shipping. All these ...
(Date:9/17/2014)... 2014 Mercy College is proud to welcome ... of Social and Behavioral Sciences. As dean, she ... the academic mission of the dynamic undergraduate and graduate programs ... honored to join Mercy College. During my first three ... campuses dedicated to the educational mission of the College. ...
(Date:9/17/2014)... Lake City, UT (PRWEB) September 17, 2014 ... Miss America 2015 Kira Kazantsev and ushered in ... need charitable support. As Miss America Organization’s official ... is welcoming Kazantsev as its newest National Goodwill ... her at member Children’s Miracle Network Hospitals across ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Elegant Petite Evening Dresses Introduced By Renowned Supplier iFitDress.com 2Health News:Mercy College Welcomes New Dean of the School of Social and Behavioral Sciences 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
... Sept. 20 Approximately 100,corporate pilots and ... earn,lifesaving certifications provided by the American Heart ... Safety Standdown in Wichita, Kan.,Oct. 22-25. ... event offers safety,training to the business aviation ...
... single dose of Otsukas investigational oral medication tolvaptan, ... in hemodynamics associated with a significant increase in ... (ADHF) who participated in the international trial the ... with HEart failure (ECLIPSE), presented at the late ...
... Inc.,(TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing ... technologies for,the management of cancer, today announced that ... Vincent were elected to the Board of Directors ... 19, 2007. Dr. Burger has been,unanimously elected as ...
... A Florida pharmacy,owner and a Kentucky physician pleaded ... pharmacy business that generated more than,$126 million in ... Assistant Attorney General Alice S. Fisher of the ... the Southern District of,California announced today. Claude ...
... ... Zoo, Chicago, FAIRFAX, Va., Sept. 19 ... heavy vaginal,bleeding caused by uterine fibroids, noncancerous tumors that develop in,the muscular ... of Chicago, IL, and is a 46-year-old menopausal western lowland,gorilla. Doctors have ...
... Event to Take Place Friday February 8th, 2008, ... Inc. of Rancho Mirage, will host its first,annual Gala, ... A. Lopez, Director of Internal Medicine Specialists-Rancho,Mirage. The elegant ... Resort in Rancho Mirage and will begin at 6:00 ...
Cached Medicine News:Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 2Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 3Health News:ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 3Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 4Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 2Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 3Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 2Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 3Health News:IMA South American Extravaganza Dinner to Honor Coachella Valley Doctor 2
... high-end microplate reader with outstanding sensitivity and ... Fluorescence Intensity - FRET , Fluorescence Polarization ... , Luminescence , , , ... reader with fastest read times. The ultimate ...
GENios Pro, TECANs advanced, multi-functional injector reader offers simultaneous reagent dispensing and detection for monitoring of fast kinetic reactions...
... Throughput Screening (UHTS), Analyst GT delivers ... for smooth transfer of assays into ... all the detection modalities of Analyst ... polarization, time-resolved fluorescence, luminescence, absorbance, as ...
... a fully automated microplate based multi-detection ... principles:, , Fluorescence Polarization , ... , High-Performance Luminescence (flash and glow) ... is designed for the widest possible ...
Medicine Products: